Loading...
XJPX
4538
Market cap113mUSD
Jul 10, Last price  
2,156.00JPY
1D
0.28%
1Q
-6.10%
Jan 2017
-22.53%
Name

Fuso Pharmaceutical Industries Ltd

Chart & Performance

D1W1MN
XJPX:4538 chart
P/E
9.15
P/S
0.30
EPS
235.56
Div Yield, %
4.04%
Shrs. gr., 5y
-0.54%
Rev. gr., 5y
4.81%
Revenues
62.31b
+2.88%
43,167,000,00043,991,000,00045,901,000,00046,560,000,00047,469,000,00044,358,000,00048,612,000,00049,098,000,00047,042,000,00045,752,000,00046,782,000,00045,900,000,00046,074,000,00046,902,000,00049,253,000,00049,632,000,00051,015,000,00055,407,000,00060,563,000,00062,307,000,000
Net income
2.01b
P
-2,038,000,000107,000,000-931,000,000518,000,0001,144,000,000372,000,0004,871,000,0001,979,000,000340,000,00010,000,000861,000,000970,000,000894,000,000707,000,0001,607,000,0001,483,000,0001,605,000,0001,377,000,000-3,288,000,0002,011,000,000
CFO
-6.22b
L+88.32%
1,614,000,0001,987,000,0001,183,000,0002,186,000,0006,944,000,000885,000,0003,258,000,0002,889,000,0001,943,000,0002,203,000,0002,030,000,0001,527,000,0002,146,000,0005,840,000,0003,275,000,0003,606,000,0002,865,000,000627,000,000-3,305,000,000-6,224,000,000
Dividend
Sep 29, 202645 JPY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Fuso Pharmaceutical Industries, Ltd. is a Japanese firm primarily involved in the development and commercialization of pharmaceutical goods. Their product range encompasses prescription medications, particularly injectables and solutions for artificial kidney dialysis, as well as various medical instruments and apparatus. Additionally, the company participates in real estate leasing. Established in 1937, Fuso Pharmaceutical's corporate headquarters are situated in Osaka, Japan.
URL
https://www.fuso-pharm.co.jp/
IPO date
Dec 22, 1989
Employees
1,370
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT